AOCNP Exam Review - Board Exam Prep - Questions &
Answers | 2026/2027 Edition | 250 Verified Questions
AOCNP Board Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines | Graded A+
This comprehensive review guide is meticulously designed for advanced oncology nurse practitioners
preparing for the AOCNP board certification. It contains 250 verified questions that mirror the exam's
format and content, covering all major domains of oncology nursing practice. Each question is
accompanied by detailed rationales and evidence-based explanations to reinforce learning and ensure
readiness. Updated for the 2026-2027 academic year, this resource reflects the latest clinical guidelines
and certification standards.
Key Features:
Symptom Management and Supportive Care
Oncologic Emergencies and Complications
Treatment Modalities and Targeted Therapies
Screening, Prevention, and Early Detection
Psychosocial and Ethical Issues in Oncology
Evidence-Based Practice and Research Utilization
Updates for 2026:
- Incorporated latest NCCN and ASCO guidelines for 2026-2027
- Added new questions on immunotherapy and targeted therapy toxicities
- Updated rationales to reflect current evidence-based practice
- Revised content on cancer genetics and risk assessment
- Enhanced coverage of survivorship care and long-term follow-up
Abstract:
This AOCNP Exam Review is a rigorous, comprehensive tool for advanced oncology nurse practitioners seeking
board certification. The 250 questions are distributed across all major content areas, including epidemiology,
prevention, screening, diagnosis, treatment, and survivorship. Each question is designed to test clinical reasoning
and application of knowledge in real-world scenarios. The rationales provide in-depth explanations of correct and
incorrect options, facilitating a deeper understanding of oncology nursing principles. Updated to align with the
latest evidence and guidelines, this review ensures that candidates are well-prepared for the exam's challenges. It
is an essential resource for achieving a passing score and demonstrating clinical competence in oncology nursing.
Keywords:
AOCNP, Oncology Nursing, Board Exam Prep, Certification Review, Cancer Care, Clinical Practice,
Evidence-Based Guidelines
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Incorrect
options are also analyzed to clarify common misconceptions. Rationales are concise yet comprehensive,
referencing current guidelines and research.
Compliance Checklist:
Aligned with ONCC AOCNP Test Content Outline
Updated to 2026-2027 clinical practice guidelines
Includes evidence-based rationales for all answers
Page 1
, Covers all major domains of oncology nursing
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Screening, Prevention, and Early 1-50 Cancer risk assessment, genetic counseling, 20%
Detection screening guidelines, prevention strategies
Diagnosis and Staging 51-100 Diagnostic imaging, biopsy techniques, 20%
tumor markers, staging systems
Treatment Modalities 101-150 Surgery, radiation therapy, chemotherapy, 20%
immunotherapy, targeted therapy
Symptom Management and 151-200 Pain management, nausea/vomiting, fatigue, 20%
Supportive Care nutrition, palliative care
Oncologic Emergencies and 201-230 Neutropenic fever, tumor lysis syndrome, 12%
Complications spinal cord compression, hypercalcemia
Psychosocial, Ethical, and 231-250 Patient education, communication, ethical 8%
Professional Issues dilemmas, survivorship care
Page 2
,Q1. A 58-year-old patient with metastatic colorectal cancer (KRAS wild-type) is being
considered for anti-EGFR therapy. Which of the following molecular findings would
be a contraindication to this treatment?
A. BRAF V600E mutation
B. HER2 amplification
C. MSI-H status
D. PIK3CA mutation
Correct Answer: A. BRAF V600E mutation
Rationale: Anti-EGFR antibodies (cetuximab, panitumumab) are ineffective in tumors with
downstream pathway mutations like BRAF V600E, which bypass EGFR inhibition. HER2
amplification, MSI-H, and PIK3CA mutations are not absolute contraindications, though
they may affect response.
Why Wrong:
B - HER2 amplification is not a contraindication to anti-EGFR therapy, though it may
be a target for alternative therapy.
C - MSI-H status indicates potential benefit from immunotherapy, not a
contraindication to anti-EGFR.
D - PIK3CA mutations are not established as a contraindication to anti-EGFR therapy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 87
Q2. Which of the following best explains the mechanism of action of PARP inhibitors
in tumors with BRCA1/2 mutations?
A. Induction of single-strand breaks that are unrepaired due to homologous
recombination deficiency
B. Inhibition of the proteasome, leading to accumulation of pro-apoptotic proteins
C. Blockade of the PD-1/PD-L1 interaction to enhance T-cell-mediated killing
D. Intercalation into DNA and inhibition of topoisomerase II, causing double-strand
breaks
Correct Answer: A. Induction of single-strand breaks that are unrepaired due to
homologous recombination deficiency
Rationale: PARP inhibitors trap PARP on single-strand breaks, preventing their repair. In
BRCA-mutated cells, homologous recombination repair is defective, leading to
accumulation of double-strand breaks and cell death (synthetic lethality).
Why Wrong:
B - Proteasome inhibition is the mechanism of bortezomib, not PARP inhibitors.
C - PD-1/PD-L1 blockade is the mechanism of immune checkpoint inhibitors.
D - Topoisomerase II inhibition is the mechanism of drugs like etoposide.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 90
Page 3
, Q3. A patient receiving high-dose methotrexate for osteosarcoma develops acute
kidney injury. Which intervention is most likely to prevent further nephrotoxicity?
A. Intravenous sodium bicarbonate to alkalinize the urine
B. Aggressive hydration with normal saline
C. Administration of leucovorin rescue
D. Hemodialysis to remove methotrexate
Correct Answer: A. Intravenous sodium bicarbonate to alkalinize the urine
Rationale: Alkalinization of urine increases methotrexate solubility, preventing
precipitation in renal tubules. This is the primary preventive measure for
methotrexate-induced nephrotoxicity. Hydration helps but is not sufficient alone.
Leucovorin rescues normal cells but does not prevent kidney damage. Hemodialysis is
used after toxicity occurs.
Why Wrong:
B - Hydration is important but without alkalinization, methotrexate can still
precipitate.
C - Leucovorin rescue protects against myelosuppression, not nephrotoxicity.
D - Hemodialysis is reserved for severe toxicity, not prevention.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 88
Q4. Which of the following is the most appropriate first-line treatment for a patient
with newly diagnosed chronic lymphocytic leukemia (CLL) who has del(17p) and is
physically fit?
A. Ibrutinib
B. Fludarabine, cyclophosphamide, and rituximab (FCR)
C. Bendamustine and rituximab (BR)
D. Chlorambucil and obinutuzumab
Correct Answer: A. Ibrutinib
Rationale: Patients with del(17p) have poor responses to chemoimmunotherapy. BTK
inhibitors like ibrutinib are the preferred first-line option due to their efficacy regardless
of TP53 alterations. FCR and BR are less effective in this high-risk group.
Chlorambucil-based regimens are for less fit patients.
Why Wrong:
B - FCR is less effective in del(17p) CLL due to fludarabine resistance.
C - BR is also chemoimmunotherapy and less effective in high-risk CLL.
D - Chlorambucil is not preferred for fit patients with high-risk disease.
Reference: NCCN Guidelines for CLL, 2025
Page 4
Answers | 2026/2027 Edition | 250 Verified Questions
AOCNP Board Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines | Graded A+
This comprehensive review guide is meticulously designed for advanced oncology nurse practitioners
preparing for the AOCNP board certification. It contains 250 verified questions that mirror the exam's
format and content, covering all major domains of oncology nursing practice. Each question is
accompanied by detailed rationales and evidence-based explanations to reinforce learning and ensure
readiness. Updated for the 2026-2027 academic year, this resource reflects the latest clinical guidelines
and certification standards.
Key Features:
Symptom Management and Supportive Care
Oncologic Emergencies and Complications
Treatment Modalities and Targeted Therapies
Screening, Prevention, and Early Detection
Psychosocial and Ethical Issues in Oncology
Evidence-Based Practice and Research Utilization
Updates for 2026:
- Incorporated latest NCCN and ASCO guidelines for 2026-2027
- Added new questions on immunotherapy and targeted therapy toxicities
- Updated rationales to reflect current evidence-based practice
- Revised content on cancer genetics and risk assessment
- Enhanced coverage of survivorship care and long-term follow-up
Abstract:
This AOCNP Exam Review is a rigorous, comprehensive tool for advanced oncology nurse practitioners seeking
board certification. The 250 questions are distributed across all major content areas, including epidemiology,
prevention, screening, diagnosis, treatment, and survivorship. Each question is designed to test clinical reasoning
and application of knowledge in real-world scenarios. The rationales provide in-depth explanations of correct and
incorrect options, facilitating a deeper understanding of oncology nursing principles. Updated to align with the
latest evidence and guidelines, this review ensures that candidates are well-prepared for the exam's challenges. It
is an essential resource for achieving a passing score and demonstrating clinical competence in oncology nursing.
Keywords:
AOCNP, Oncology Nursing, Board Exam Prep, Certification Review, Cancer Care, Clinical Practice,
Evidence-Based Guidelines
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Incorrect
options are also analyzed to clarify common misconceptions. Rationales are concise yet comprehensive,
referencing current guidelines and research.
Compliance Checklist:
Aligned with ONCC AOCNP Test Content Outline
Updated to 2026-2027 clinical practice guidelines
Includes evidence-based rationales for all answers
Page 1
, Covers all major domains of oncology nursing
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Screening, Prevention, and Early 1-50 Cancer risk assessment, genetic counseling, 20%
Detection screening guidelines, prevention strategies
Diagnosis and Staging 51-100 Diagnostic imaging, biopsy techniques, 20%
tumor markers, staging systems
Treatment Modalities 101-150 Surgery, radiation therapy, chemotherapy, 20%
immunotherapy, targeted therapy
Symptom Management and 151-200 Pain management, nausea/vomiting, fatigue, 20%
Supportive Care nutrition, palliative care
Oncologic Emergencies and 201-230 Neutropenic fever, tumor lysis syndrome, 12%
Complications spinal cord compression, hypercalcemia
Psychosocial, Ethical, and 231-250 Patient education, communication, ethical 8%
Professional Issues dilemmas, survivorship care
Page 2
,Q1. A 58-year-old patient with metastatic colorectal cancer (KRAS wild-type) is being
considered for anti-EGFR therapy. Which of the following molecular findings would
be a contraindication to this treatment?
A. BRAF V600E mutation
B. HER2 amplification
C. MSI-H status
D. PIK3CA mutation
Correct Answer: A. BRAF V600E mutation
Rationale: Anti-EGFR antibodies (cetuximab, panitumumab) are ineffective in tumors with
downstream pathway mutations like BRAF V600E, which bypass EGFR inhibition. HER2
amplification, MSI-H, and PIK3CA mutations are not absolute contraindications, though
they may affect response.
Why Wrong:
B - HER2 amplification is not a contraindication to anti-EGFR therapy, though it may
be a target for alternative therapy.
C - MSI-H status indicates potential benefit from immunotherapy, not a
contraindication to anti-EGFR.
D - PIK3CA mutations are not established as a contraindication to anti-EGFR therapy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 87
Q2. Which of the following best explains the mechanism of action of PARP inhibitors
in tumors with BRCA1/2 mutations?
A. Induction of single-strand breaks that are unrepaired due to homologous
recombination deficiency
B. Inhibition of the proteasome, leading to accumulation of pro-apoptotic proteins
C. Blockade of the PD-1/PD-L1 interaction to enhance T-cell-mediated killing
D. Intercalation into DNA and inhibition of topoisomerase II, causing double-strand
breaks
Correct Answer: A. Induction of single-strand breaks that are unrepaired due to
homologous recombination deficiency
Rationale: PARP inhibitors trap PARP on single-strand breaks, preventing their repair. In
BRCA-mutated cells, homologous recombination repair is defective, leading to
accumulation of double-strand breaks and cell death (synthetic lethality).
Why Wrong:
B - Proteasome inhibition is the mechanism of bortezomib, not PARP inhibitors.
C - PD-1/PD-L1 blockade is the mechanism of immune checkpoint inhibitors.
D - Topoisomerase II inhibition is the mechanism of drugs like etoposide.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 90
Page 3
, Q3. A patient receiving high-dose methotrexate for osteosarcoma develops acute
kidney injury. Which intervention is most likely to prevent further nephrotoxicity?
A. Intravenous sodium bicarbonate to alkalinize the urine
B. Aggressive hydration with normal saline
C. Administration of leucovorin rescue
D. Hemodialysis to remove methotrexate
Correct Answer: A. Intravenous sodium bicarbonate to alkalinize the urine
Rationale: Alkalinization of urine increases methotrexate solubility, preventing
precipitation in renal tubules. This is the primary preventive measure for
methotrexate-induced nephrotoxicity. Hydration helps but is not sufficient alone.
Leucovorin rescues normal cells but does not prevent kidney damage. Hemodialysis is
used after toxicity occurs.
Why Wrong:
B - Hydration is important but without alkalinization, methotrexate can still
precipitate.
C - Leucovorin rescue protects against myelosuppression, not nephrotoxicity.
D - Hemodialysis is reserved for severe toxicity, not prevention.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 88
Q4. Which of the following is the most appropriate first-line treatment for a patient
with newly diagnosed chronic lymphocytic leukemia (CLL) who has del(17p) and is
physically fit?
A. Ibrutinib
B. Fludarabine, cyclophosphamide, and rituximab (FCR)
C. Bendamustine and rituximab (BR)
D. Chlorambucil and obinutuzumab
Correct Answer: A. Ibrutinib
Rationale: Patients with del(17p) have poor responses to chemoimmunotherapy. BTK
inhibitors like ibrutinib are the preferred first-line option due to their efficacy regardless
of TP53 alterations. FCR and BR are less effective in this high-risk group.
Chlorambucil-based regimens are for less fit patients.
Why Wrong:
B - FCR is less effective in del(17p) CLL due to fludarabine resistance.
C - BR is also chemoimmunotherapy and less effective in high-risk CLL.
D - Chlorambucil is not preferred for fit patients with high-risk disease.
Reference: NCCN Guidelines for CLL, 2025
Page 4
